• N&PD Moderators: Skorpio | thegreenhand

Ketamine salts solubility

Status
Not open for further replies.
7-methoxy-1,3-dihydro-1-methyl-5-(2-methylphenyl)-2H-1,4-benzodiazepine-2-one.png


DIAZEPARTY
7-methoxy-1,3-dihydro-1-methyl-5-(2-methylphenyl)-2H-1,4-benzodiazepine-2-one
 
(2S,5R,6R)-2-carbomethoxy-3,3-dimethyl-7-oxo-6-((2-(4-nitrophenyl)-2-amino-1-(oxomethyl)ethyl)amino)-4-thia-1-azabicyclo%5b3.2.0%5dheptane.png


BACTERIOCIDE_G-ZUP
(2S,5R,6R)-2-carbomethoxy-3,3-dimethyl-7-oxo-6-((2-(4-nitrophenyl)-2-amino-1-(oxomethyl)ethyl)amino)-4-thia-1-azabicyclo[3.2.0]heptane

Inspired by penicillanic acid, chloramphenicol, and amoxicillin.
 
In another thread, I mentioned the possibility that the doubling of brain kynurenic acid levels by high doses of L-tryptophan (5 g/day) could possibly potentiate the effect of dissociatives, as kynurenate blocks the glycine binding site on NMDA receptors. Looking at some publications, it also seems that COX-1 inhibitors such as aspirin and paracetamol (acetaminophen) cause a similar increase in brain kynurenic acid concentration. In this article, this has been tested in rats with indomethacin. NMDAr glycine site blockers are also known to cause an anxiolytic effect, and this is also seen with paracetamol and aspirin, which makes me suspect that this effect of NSAIDs could be caused by them affecting metabolic kynurenate production. The anti-anxiety effect of paracetamol is usually attributed to its influence on endocannabinoid metabolism, but the kynurenic acid pathway could also be a factor in this. The possibility of aspirin or paracetamol potentiating the effect of ketamine, PCP and other dissociatives is somewhat significant, because someone could easily take that combination without knowing that there can be a synergistic effect.

Curiously, the non-steroidal anti-inflammatory drug indomethacin has also caused psychotic symptoms to some people, as have some other drugs of that class as well, and it wouldn't be surprising if this is caused by it affecting the NMDA receptor.

Edit: looks like there is this thread on BL about HA-966, which is an NMDA glycine site blocker or partial agonist.
 
Last edited:
Won't be very potent - the 6 methoxy interacts with the -OH on that side-chain. MAYBE that O-methyl moves between the two spots?

N-CF3?

Won't ionize.

Why has nobody suggested an N-phenylethyl or homologue. I've posted a link to the hundreds of levophhanol analouges made and tested. The N-phenylethyl was x80M, the N-2-(2-thienyl)ethyl x240M and N-2-(2-furanyl)ethyl x480M.
don’t need to ionize opioids to use them. See No. 3 heroin

The RECEPTOR requires a positively ionizable function - I've posted multiple papers on this.
 
Why has nobody suggested an N-phenylethyl or homologue. I've posted a link to the hundreds of levophhanol analouges made and tested. The N-phenylethyl was x80M, the N-2-(2-thienyl)ethyl x240M and N-2-(2-furanyl)ethyl x480M.


The RECEPTOR requires a positively ionizable function - I've posted multiple papers on this.
Sorry I don’t read every paper you post on BL. Please forgive me.

I was stoned off my ass and made up chemdraw structures without reading shit about SAR.
 
Last edited:
But lets go through it as I did, beginning with the patent.

US 3904641 - Triazolothienodiazepine compounds by Michio Nakanishi, Tetsuya, Tahara Kazuhiko Araki & Masami Shiroki

When you have read, understood and digested that, we shall proceed. Because I'm 100% going to ensure you do the work I did.
 
I don't use drugs other than those prescribed by my doctor. I'm not addicted to them although they do both produce a defined abstinence syndrome. I don't drink alcohol although I do smoke tobacco occasionally.

BUT having spent 8 years of higher education in the subject and now being severely disables does mean I have a huge amount of time to expend.
 
Status
Not open for further replies.
Top